Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Nova (NasdaqGS:NVMI) with a Overweight ...

We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...

Cantor Fitzgerald initiated coverage of Onto Innovation (ONTO) with an Overweight rating and $250 price target Stay Ahead of the ...

Cantor Fitzgerald downgraded Intra-Cellular (ITCI) to Neutral from Overweight with a price target of $132, down from $135, after Johnson & ...

We recently compiled a list of the 14 AI Stocks Making Waves on Wall Street. In this article, we are going to take a look at ...

Cantor Fitzgerald initiated coverage on shares of Check Point Software Technologies (NASDAQ:CHKP – Free Report) in a research ...

Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share estimates for Maplebear in a research note issued on Tuesday, January 7th. Cantor Fitzgerald analyst D. Mathivanan now ...

Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it closed its initial public offering ...

Fintel reports that on January 10, 2025, Cantor Fitzgerald initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Overweight recommendation. As of December 23, 2024, the average one ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it priced its initial public offering ...